Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 4/20 | 0.65 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 9/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723994 | 1.00 | GRK2 (0.65) | GRK2GRK1GRK5MMP13MCL1 | |
| SCHEMBL1500346 | 0.89 | GRK2 (0.60) | GRK2GRK1GRK5MMP13 | |
| SCHEMBL30669835 | 0.86 | MCL1 (0.54) | GRK2MMP13MCL1SCD | |
| SCHEMBL28634877 | 0.86 | MCL1 (0.54) | GRK2MMP13MCL1SCD | |
| SCHEMBL9145974 | 0.86 | GRK2 (0.56) | GRK2GRK1GRK5MCL1 | |
| SCHEMBL24542665 | 0.84 | MAPK1 (0.54) | GRK2GRK1GRK5MMP13MCL1 | |
| SCHEMBL29065789 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13 | |
| SCHEMBL6014176 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL4969416 | 0.83 | GRK2 (0.65) | GRK2GRK1GRK5MMP13SCD | |
| SCHEMBL29147374 | 0.83 | MMP13 (0.64) | GRK2GRK5MMP13MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344355-A | Quinazolinone derivative, preparation method thereof and application thereof in anti-inflammatory and anti-tumor | 贵州省天然产物研究中心 | 2024-07-16 | — | — | CN | claimed |
| CN-118344355-A | Quinazolinone derivative, preparation method thereof and application thereof in anti-inflammatory and anti-tumor | 贵州省天然产物研究中心 | 2024-07-16 | — | — | CN | disclosed |
| CN-113501819-B | Pyridoimidazole substituted quinazolinone derivative, and synthetic method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2024-02-02 | — | — | CN | disclosed |
| CN-110655505-B | 6- (2-amino-1H-benzo [ d ] imidazol-6-yl) quinazolin-4 (3H) -ones | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2022-06-21 | — | — | CN | disclosed |
| CN-110655505-A | 6- (2-amino-1H-benzo [ d ] imidazol-6-yl) quinazolin-4 (3H) -ones | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2020-01-07 | — | — | CN | disclosed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| WO-2016133888-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| CN-103703009-B | Noval chemical compound as diacylglycerol acyltransferase inhibitors | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-103703009-A | Novel compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC | 2014-04-02 | — | — | CN | disclosed |
| EP-2710013-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140080809-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-03-20 | — | — | US | disclosed |
| WO-2012162129-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162129-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | GRK2 23/4885GRK1 17/4885GRK5 27/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | GRK2 23/4885GRK1 22/4885GRK5 32/4885 |
| US-20140080809-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | GRK2 1768/4885GRK1 2416/4885GRK5 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.